ORIGINAL RESEARCH Impact of Methodologic Choice for Automatic Detection of Different Aspects of Brain Atrophy by Using Temporal Lobe Epilepsy as a Model

Catherine E Scanlon(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center), Ian Cheong(Western University), Duygu Tosun(University of California, San Francisco), Jerome Barakos(Sutter Health), P. García(University of California, San Francisco)
Unknown
January 1, 2011
Cited by 1

Related Papers

Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells
|Science|2009|908
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
|The Lancet Neurology|2012|512